NCT02598661: Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Sponsor: Geron Corporation. Phase: PHASE2. Conditions: Myelodysplastic Syndromes